Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice-Reference-Cited by-同舟云学术

Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice

Published:2018-11 Issue: Volume:26 Page:211-218
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Coyle Patricia K.,Khatri Bhupendra^ORCID,Edwards Keith R.,Meca-Lallana José E.,Cavalier Steve,Rufi Pascal,Benamor Myriam,Thangavelu Karthinathan,Robinson Miqun,Gold Ralf

Funder

Sanofi

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference44 articles.

1. Cognitive changes in early MS: a call for a common framework;Achiron;J. Neurol. Sci.,2006

2. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease;Atkinson;Health Qual. Life Outcomes,2004

3. Assessing quality of life in patients with multiple sclerosis;Bandari;Int. J. MS Care,2010

4. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence;Barbosa;Patient Prefer. Adherence,2012

5. Factors associated with employment status in individuals with multiple sclerosis;Cadden;Int. J. MS Care,2015

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The patient-reported outcomes for the new brand-generic teriflunomide in relapsing-remitting multiple sclerosis;Clinical Neurology and Neurosurgery;2024-11

2. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study;Neurology and Therapy;2023-10-20

3. Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review;Bioengineering;2023-07-18

4. The impact of disease modifying therapies on cognitive functions typically impaired in multiple sclerosis patients: a clinician’s review;Frontiers in Neurology;2023-07-12

5. Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States;ClinicoEconomics and Outcomes Research;2023-05